Kissei Pharmaceutical Toekomstige groei
Future criteriumcontroles 0/6
Kissei Pharmaceutical's earnings are forecast to decline at 6.8% per annum while its annual revenue is expected to grow at 4.1% per year. EPS is expected to decline by 6.6% per annum. Return on equity is forecast to be 3.7% in 3 years.
Belangrijke informatie
-6.8%
Groei van de winst
-6.6%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 11.9% |
| Inkomstengroei | 4.1% |
| Toekomstig rendement op eigen vermogen | 3.7% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 03 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00
Sep 24
Kissei Pharmaceutical (TSE:4547) Is Increasing Its Dividend To ¥45.00
Sep 09Kissei Pharmaceutical's (TSE:4547) Dividend Will Be Increased To ¥45.00
Jul 25Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00
Jul 11Kissei Pharmaceutical's (TSE:4547) Shareholders May Want To Dig Deeper Than Statutory Profit
May 21Kissei Pharmaceutical Co., Ltd. (TSE:4547) Yearly Results: Here's What Analysts Are Forecasting For This Year
May 09Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00
Mar 27Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00
Mar 13Kissei Pharmaceutical (TSE:4547) Has Announced A Dividend Of ¥41.00
Feb 27Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 3/31/2027 | 89,364 | 8,057 | 8,414 | N/A | 3 |
| 3/31/2026 | 85,449 | 9,067 | 11,712 | N/A | 3 |
| 3/31/2025 | 83,855 | 11,967 | 5,031 | N/A | 4 |
| 6/30/2024 | 77,430 | 12,001 | N/A | N/A | N/A |
| 3/31/2024 | 75,579 | 11,160 | -3,510 | -1,677 | N/A |
| 12/31/2023 | 73,717 | 12,198 | N/A | N/A | N/A |
| 9/30/2023 | 71,607 | 12,880 | -8,350 | -5,854 | N/A |
| 6/30/2023 | 70,521 | 12,158 | N/A | N/A | N/A |
| 3/31/2023 | 67,493 | 10,528 | -9,226 | -6,679 | N/A |
| 12/31/2022 | 66,931 | 12,769 | N/A | N/A | N/A |
| 9/30/2022 | 65,857 | 10,581 | -4,543 | -2,556 | N/A |
| 6/30/2022 | 65,031 | 10,912 | N/A | N/A | N/A |
| 3/31/2022 | 65,381 | 12,921 | -386 | 1,533 | N/A |
| 12/31/2021 | 66,934 | 5,664 | N/A | N/A | N/A |
| 9/30/2021 | 69,148 | 6,555 | -2,042 | -349 | N/A |
| 6/30/2021 | 69,618 | 7,204 | N/A | N/A | N/A |
| 3/31/2021 | 69,044 | 5,285 | -4,027 | -2,542 | N/A |
| 12/31/2020 | 66,877 | 5,715 | N/A | N/A | N/A |
| 9/30/2020 | 63,970 | 5,063 | -573 | 683 | N/A |
| 6/30/2020 | 63,196 | 2,530 | N/A | N/A | N/A |
| 3/31/2020 | 63,234 | 2,817 | 12,632 | 13,934 | N/A |
| 12/31/2019 | 65,594 | 4,753 | N/A | N/A | N/A |
| 9/30/2019 | 68,180 | 4,294 | 9,189 | 10,431 | N/A |
| 6/30/2019 | 70,545 | 4,752 | N/A | N/A | N/A |
| 3/31/2019 | 72,297 | 5,481 | 5,013 | 6,346 | N/A |
| 12/31/2018 | 72,474 | 5,263 | N/A | N/A | N/A |
| 9/30/2018 | 73,087 | 8,102 | 12,159 | 13,854 | N/A |
| 6/30/2018 | 73,014 | 9,685 | N/A | N/A | N/A |
| 3/31/2018 | 74,009 | 9,045 | N/A | 8,845 | N/A |
| 12/31/2017 | 73,887 | 8,735 | N/A | N/A | N/A |
| 9/30/2017 | 72,459 | 8,116 | N/A | 5,756 | N/A |
| 6/30/2017 | 71,396 | 6,993 | N/A | N/A | N/A |
| 3/31/2017 | 71,706 | 7,726 | N/A | 6,441 | N/A |
| 12/31/2016 | 72,154 | 6,401 | N/A | N/A | N/A |
| 9/30/2016 | 73,533 | 8,108 | N/A | 9,023 | N/A |
| 6/30/2016 | 73,774 | 8,734 | N/A | N/A | N/A |
| 3/31/2016 | 71,294 | 8,165 | N/A | 5,763 | N/A |
| 12/31/2015 | 71,239 | 8,521 | N/A | N/A | N/A |
| 9/30/2015 | 69,095 | 6,608 | N/A | 2,948 | N/A |
| 6/30/2015 | 70,945 | 7,161 | N/A | N/A | N/A |
| 3/31/2015 | 70,110 | 7,165 | N/A | 6,667 | N/A |
| 12/31/2014 | 69,666 | 7,829 | N/A | N/A | N/A |
| 9/30/2014 | 73,090 | 9,817 | N/A | 9,538 | N/A |
| 6/30/2014 | 69,934 | 8,935 | N/A | N/A | N/A |
| 3/31/2014 | 70,399 | 9,093 | N/A | 11,945 | N/A |
| 12/31/2013 | 69,335 | 9,365 | N/A | N/A | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 4547's earnings are forecast to decline over the next 3 years (-6.8% per year).
Winst versus markt: 4547's earnings are forecast to decline over the next 3 years (-6.8% per year).
Hoge groeiwinsten: 4547's earnings are forecast to decline over the next 3 years.
Omzet versus markt: 4547's revenue (4.1% per year) is forecast to grow slower than the JP market (4.2% per year).
Hoge groei-inkomsten: 4547's revenue (4.1% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: 4547's Return on Equity is forecast to be low in 3 years time (3.7%).